October 2, 2024 Sophia Vida
Breaking News

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 – BioStem Technologies, Inc. (OTC: … Continue reading “BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers”